The Evaluation of the Glucose-Lowering Effect of Bloodletting Therapy in Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.24079/cajms.2024.04.002Keywords:
Bloodletting, Type 2 Diabetes Mellitus, Glucose, Insulin, C-Peptide, Blood Lipid ProfileAbstract
Objective: This study uses a quantitative method to evaluate bloodletting therapy’s impact on lowering blood glucose levels and improving metabolic parameters in patients with type 2 diabetes mellitus (T2DM). Method: This randomized, controlled clinical trial included 110 patients diagnosed with T2DM who met the study’s inclusion criteria. Participants were randomly assigned to a control group (standard medication) and an experimental group (standard medication plus bloodletting therapy). Both groups received medicine according to the Mongolian Clinical Practice Guidelines for T2DM treatment. The experimental group additionally underwent bloodletting therapy on Day 6 of the study, following a 5-day preparation period during which they consumed 2.0 grams of a “3-seed decoction” (twice daily). The bloodletting procedure involves drawing blood from the posterior antebrachial vein (100-150 mL). The study evaluated primary outcomes, including fasting blood glucose and HbA1c levels, and secondary outcomes, such as insulin levels, C-peptide concentrations, and lipid profiles (total cholesterol, triglycerides, LDL, and HDL) at baseline, Day 30, and Day 60. Results: The experimental group demonstrated significant improvements in metabolic parameters. BMI levels decreased from 30.45±4.48 at baseline to 29.09±3.60 at Day 60 (P < 0.05), and HbA1c decreased from 9.2 ± 2.46% to 8.49 ± 1.85% (P< 0.05). Furthermore, significant reductions were observed in insulin levels (from 43.38 ± 14.12 to 25.61 ± 4.8 pmol/L; P= 0.0001) and C-peptide levels (from 4.9 to 4.2 ng/mL; P= 0.0004). The lipid profile also showed improvements, with a reduction in LDL cholesterol and triglycerides compared to the control group, although these changes were not statistically significant at Day 60. Conclusion: Integrating bloodletting therapy into the treatment regimen for T2DM provides additional benefits, including significant reductions in blood glucose, HbA1c, insulin, and C-peptide levels. Bloodletting therapy, when used in combination with standard pharmacotherapy, could offer a cost-effective and clinically beneficial treatment option for managing type 2 diabetes.
Downloads
30
References
1. Roglic G. WHO Global report on diabetes: A summary. Int J Noncommun Dis. 2016;1(1):3-8. http://dx.doi.org/10.4103/2468-8827.184853
2. Magliano DJ, Boyko EJ. IDF diabetes atlas. 2022. https://www.ncbi.nlm.nih.gov/books/NBK581934
3. Simonen P P, Helena K G, Miettinen T A. Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes care. 2002.25(9):1511-1515. https://doi.org/10.2337/diacare.25.9.1511
4. Feingold K R.Obesity and dyslipidemia. 2015. https://europepmc.org/article/NBK/nbk305895/
5. Charlton A, Garzarella J, Jandeleit-Dahm KA, et al. Oxidative stress and inflammation in renal and cardiovascular complications of diabetes. Biology (Basel) 2020;10(1):18. https://doi.org/10.3390/biology10010018
6. Harding JL, Pavkov ME, Magliano DJ, et al. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62:3-16. https://doi.org/10.1007/s00125-018-4711-2
7. Teodoro JS, Nunes S, Rolo AP, et al. Therapeutic options targeting oxidative stress, mitochondrial dysfunction and inflammation to hinder the progression of vascular complications of diabetes. Front Physiol. 2019;9:1857. https://doi.org/10.3389/fphys.2018.01857
8. Pappan N, Awosika AO, Rehman A. Dyslipidemia. StatPearls. StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK560891/
9. Casanova-Esteban P, Guiral N, Andrés E, et al. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis. Metabolism. 2011;60(6):830-834. https://doi.org/10.1016/j.metabol.2010.07.035
10. Tserendagva D. Essence and waste product secretion pattern, impure blood, blood secretion decoction /tang/ and their correlation. Ulaanbaatar, Mongolia. Munkhiin useg printing;2019.p247-249
11. Oldokh S. Variants of bloodletting vessels and their bioelectric activity matter [dissertation]. Ulaanbaatar, Mongolia. National University of Medicine; 1997
12. MOH. Clinical practice guidelines for type 2 diabetes mellitus, in order of Health Minister A/96. Ulaanbaatar 2021, https://moh.gov.mn/uploads/files/f14a0995e970cae49bdd1cd2deca53d5b6ddebea.pdf.
13. MOH. Clinical practice guidelines for bloodletting treatment, in order of Health Minister A/152. Ulaanbaatar 2021, https://www.moh.gov.mn/uploads/files/b457e3e0210de6b0dfc2aa879e9e1465115532e7.pdf
14. Miller BR, Nguyen H, Hu CJ-H et al, New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benefits. 2014:7(8):452-463.
15. Williams R, Karuranga S, Malanda B, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2020;162:108072. https://doi.org/10.1016/j.diabres.2020.108072
16. Association Diabetes Association. Economic costs of diabetes in the US in 2017. Diabetes care. 2018;41(5):917-928. https://doi.org/10.2337/dci18-0007
17. Yang W, Zhao W, Xiao J, et al. Medical care and payment for diabetes in China: enormous threat and great opportunity. PLoS One 2012. https://doi.org/10.1371/journal.pone.0039513
18. Peters M, Huisman E, Schoonen M, et al. The current total economic burden of diabetes mellitus in the Netherlands. Neth J Med. 2017;75(7):281-297.
19. Misheel G, Gantugs.Y. Result of the study of cost estimates for individuals with type 2 diabetes. J Health Sci. 2024;3
20. Fernández-Real JM, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and β-cell function. Diabetes. 2002;51(4):1000-1004. https://doi.org/10.2337/diabetes.51.4.1000
21. Dijkstra A, Lenters-Westra E, de Kort W, et al. Whole blood donation affects the interpretation of hemoglobin A1c. PLoS One 2017;12(1):e0170802. https://doi.org/10.1371/journal.pone.0170802
22. Braun J, Bopp M, Faeh D. Blood glucose may be an alternative to cholesterol in CVD risk prediction charts. Cardiovasc Diabetol. 2013;12:24. https://doi.org/10.1186/1475-2840-12-24
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mongolian National University of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
